Similar Papers

Paper Title
Journal
Date
Author
Efficacy and safety of immunotherapy in cervical cancer: a review of advances in immune-related therapy for cervical cancer
Jing Liu ... Qin Xu
Holistic Integrative Oncology | VOL. 4
Jing Liu, et. al.Jing Liu ... Qin Xu
18 Mar 2025
Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.
Mona W Schmidt ... Marcus Schmidt
Cancers | VOL. 14
Mona W Schmidt, et. al.Mona W Schmidt ... Marcus Schmidt
17 Jan 2022
Recent advances in immunotherapy for cervical cancer
Aiko Ogasawara ... Kosei Hasegawa
International Journal of Clinical Oncology | VOL. 30
Aiko Ogasawara, et. al.Aiko Ogasawara ... Kosei Hasegawa
31 Jan 2025
Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials.
Yang Xing ... Ying Zhang
Frontiers in immunology | VOL. 14
Yang Xing, et. al.Yang Xing ... Ying Zhang
03 Feb 2023
View more papers

More From: Critical reviews in oncology/hematology

Paper Title
Journal
Date
Author
Post-Treatment Adverse Events Ranking in Targeted Immunotherapy for Hepatocellular Carcinoma: A Network Meta-Analysis based on Risk Probability Assessment.
Gaoyuan Yang ... Zhicheng Yao
Critical reviews in oncology/hematology | VOL. -
Gaoyuan Yang, et. al.Gaoyuan Yang ... Zhicheng Yao
17 Apr 2025
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.
Chiara Catania ... Alessandro Russo
Critical reviews in oncology/hematology | VOL. 208
Chiara Catania, et. al.Chiara Catania ... Alessandro Russo
01 Apr 2025
Cellular senescence in tumor immune escape: Mechanisms, implications, and therapeutic potential.
Li You ... Qinghua Wu
Critical reviews in oncology/hematology | VOL. 208
Li You, et. al.Li You ... Qinghua Wu
01 Apr 2025
Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer.
Vindya Ranasinghe ... Nigel Mcmillan
Critical reviews in oncology/hematology | VOL. -
Vindya Ranasinghe, et. al.Vindya Ranasinghe ... Nigel Mcmillan
01 Apr 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.